NTI
Click for more information
1.39% 7.1¢ neurotech international limited

Ann: Phase II/III autism trial shows further benefits, page-10

  1. levendful
    1,294 Posts.
    lightbulb Created with Sketch. 165
    clock Created with Sketch.
    20/07/24
    17:34
    Post #: 74841808
    Yes, the orphan drug designation will get some some revenue, not sure how they will get the ASD component monetized though, I assume we would require a larger sample size to get this moving and it would be costly.
    NTI Price at posting: 7.8¢ Sentiment: Hold Disclosure: Held
    Likes Created with Sketch. 1  Upvote
    lightbulb Created with Sketch.  Great analysis
    Stroke 3 Created with Sketch. Comments Created with Sketch. Reply

  2. Top Stories

 

Featured News

RDN Raiden Resources hopeful it can start drilling Andover South, WA, as early as mid-October
right-arrow Created with Sketch.
LU7 Filling the Lithium Conversion Gap: Lithium Universe commits to community collaboration through formation of joint committee for Bécancour
right-arrow Created with Sketch.
UNT UNITH hard launching AI 'digital human' platform too 600+ companies as AI thematic survives sell-off
right-arrow Created with Sketch.
WR1 Stock watchers charged up by Winsome Resources' latest lithium drilling results
right-arrow Created with Sketch.
NOX Noxopharm aims for autoimmune market with first human trial of SOF-SKN
right-arrow Created with Sketch.
NEWS Earnings wrap Monday Week 34: A2 Milk, Bluescope, Suncorp's climate woes & more
right-arrow Created with Sketch.
watchlist Created with Sketch. Add NTI (ASX) to my watchlist
(20min delay)
Last
7.1¢ 		Change
-0.001(1.39%) 		Mkt cap ! $72.23M
Open High Low Value Volume
7.2¢ 7.4¢ 7.1¢ $38.11K 530.0K

Buyers (Bids)

No. Vol. Price($)
4 193384 7.1¢
 

Sellers (Offers)

Price($) Vol. No.
7.2¢ 17269 1
View Market Depth
Last trade - 15.56pm 21/08/2024 (20 minute delay) ?
NTI (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.